Synthetic cannabinoid receptor agonist- associated psychotic disorder: A case report

Sönmez, İpek; Köşger, Ferdi

doi:10.5080/u10109

Cited by 4 publications

(6 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, use of SCs might cause marked changes in emotional and cognitive functions, and they might trigger psychotic symptoms in individuals who especially had a tendency (1,8). Psychotic pictures which were related to SCs were frequently reported in the studies (15)(16)(17)(18). Although it was determined that psychotic symptoms might be triggered in individuals with previous psychotic disorder history while taking SCs (4,23), new onset psychotic symptoms were reported in individuals who had no previous psychotic disorder history (15)(16)(17)(18).…”

Section: Discussionmentioning

confidence: 93%

“…Psychotic pictures which were related to SCs were frequently reported in the studies (15)(16)(17)(18). Although it was determined that psychotic symptoms might be triggered in individuals with previous psychotic disorder history while taking SCs (4,23), new onset psychotic symptoms were reported in individuals who had no previous psychotic disorder history (15)(16)(17)(18). In the literature, a few adolescent cases who developed psychotic symptoms after SC use were reported (17,21).…”

Section: Discussionmentioning

confidence: 99%

“…It was reported in many studies that there was a correlation between cannabis use and both acute and chronic psychotic pictures (13,14). Similarly, number of case reports are increasing about psychotic pictures triggered by SC use (15)(16)(17)(18).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Capgras syndrome after use of synthetic cannabinoids: an adolescent case

Özer¹,

Çeri²,

Evren³

2016

Dusunen Adam

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Capgras syndrome after use of synthetic cannabinoids: an adolescent case

Özer¹,

Çeri²,

Evren³

2016

Dusunen Adam

View full text Add to dashboard Cite

“…Sönmez and Köşger (66) described a 31-year-old man who developed a new-onset SC-induced psychosis after consuming a mixture of SC called "Bonsai" three times a week for more than 6 months and was treated with olanzapine.…”

Section: Resultsmentioning

confidence: 99%

The Bridge Between Classical and “Synthetic”/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective

et al. 2019

View full text Add to dashboard Cite

The critical spread and dissemination of novel psychoactive substances (NPS), particularly among the most vulnerable youngsters, may pose a further concern about the psychotic trajectories related to the intake of new synthetic drugs. The psychopathological pattern of the “new psychoses” appears to be extremely different from the classical presentation. Therefore, clinicians need more data on these new synthetic psychoses and recommendations on how to manage them. The present mini-review aims at deepening both the clinical, psychopathological features of synthetic/chemical NPS-induced psychoses and their therapeutic strategies, according to the different NPS classes implicated, by underlining the main differences with the “classical” psychoses. A comprehensive review was conducted using the PubMed/Medline database by combining the search strategy of free-text terms and exploding a range of MESH headings relating to the topics of novel psychoactive substances and synthetic/chemical psychoses as follows: {(Novel Psychoactive Substances[Title/Abstract]) AND Psychosis[Title/Abstract])} and for each NPS categories as well, focusing on synthetic cannabinoids and cathinones, without time and/or language restrictions. Finally, an overview of the main clinical and psychopathological features between classical versus NPS-induced chemical/synthetic psychoses is provided for clinicians working with dual disorders and addiction psychiatry. Further insight is given here on therapeutic strategies and practical guidelines for managing patients affected with synthetic/chemical NPS-induced psychoses.

show abstract

“…Although SC use is relatively new compared with cannabis use, reports of associations between SC use and psychosis have been increasing (Celofiga et al, 2014;Fattore, 2016;Khan et al, 2016;Leibu et al, 2013;Sönmez & Kösç ger, 2016), with the literature largely limited to case reports. In the present study, we compared the impact of SC and cannabis on hospital length of stay and doses of antipsychotics prescribed at discharge in a relatively large inpatient population with bipolar disorder, schizophrenia, or other psychotic disorders.…”

mentioning

confidence: 99%

Hospital Stay in Synthetic Cannabinoid Users With Bipolar Disorder, Schizophrenia, or Other Psychotic Disorders Compared With Cannabis Users

Deng¹,

Desai²,

Mohite³

et al. 2019

J. Stud. Alcohol Drugs

View full text Add to dashboard Cite

The use of synthetic cannabinoid (SC) products has become popular in recent years, but data regarding their impact on hospital stays are limited. The impact of SC and cannabis use on hospital length of stay and doses of antipsychotics at discharge was assessed in this study. Method: The sample consisted of inpatients with discharge diagnoses of bipolar disorder, schizophrenia, or other psychotic disorders. Medical records of patients with self-reported SC use and negative urine drug screens (SC group, n = 77), with cannabis use confirmed by urine drug screen (cannabis group, n = 248), and with no drug use confirmed by urine drug screen (no-drug group, n = 1,336) were examined retrospectively. Results: Length of stay (mean [SD] days) significantly differed (p < .001) among the SC (8.29 [4.29]), cannabis (8.02 [5.21]), and no-drug groups (10.19 [9.08]). Antipsychotic doses (chlorpromazine milligram equivalent doses) also significantly differed (p = .002) among the SC (254.64 [253.63]), cannabis (219.16 [216.71]), and no-drug groups (294.79 [287.85]). Unadjusted and adjusted pairwise comparisons showed that the cannabis group had a shorter length of stay (p < .001) and received lower doses of antipsychotics (p = .003) than the no-drug group. SC users did not differ significantly from the other two groups in either length of stay or doses of antipsychotics. Conclusions: Our findings suggest that acute SC exposure is not predictive of a more prolonged time for response to antipsychotic medications or of a need for larger doses of these medications compared with cannabis users. (J.

show abstract

Synthetic cannabinoid receptor agonist- associated psychotic disorder: A case report

Cited by 4 publications

References 3 publications

Capgras syndrome after use of synthetic cannabinoids: an adolescent case

Capgras syndrome after use of synthetic cannabinoids: an adolescent case

The Bridge Between Classical and “Synthetic”/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective

Hospital Stay in Synthetic Cannabinoid Users With Bipolar Disorder, Schizophrenia, or Other Psychotic Disorders Compared With Cannabis Users

Contact Info

Product

Resources

About